What is the primary mechanism of action of SSRIs?
Choose an answer, then check it.
Clinical Pharmacology · Antidepressants
SSRIs
On this page 6 sections
In 30 seconds
Selective serotonin reuptake inhibitors (SSRIs) block the serotonin transporter (SERT) on presynaptic neurons, raising synaptic serotonin available to postsynaptic receptors. They are first-line agents for major depressive disorder and most anxiety-spectrum conditions because they are far safer in overdose than tricyclics or MAO inhibitors, even though they take weeks to produce a full clinical response. The six core agents (fluoxetine, sertraline, paroxetine, citalopram, escitalopram, fluvoxamine) share a mechanism but differ meaningfully in half-life, CYP450 inhibition, and side-effect emphasis. Patient teaching centers on delayed onset, adherence during the lag period, recognizable adverse effects, and two safety topics every nurse must know: serotonin syndrome and discontinuation syndrome.
The college version
Mechanism
Serotonin (5-HT) released into the synapse is normally recycled back into the presynaptic neuron by SERT, ending its signal. SSRIs bind SERT and block this reuptake, so serotonin lingers in the synaptic cleft and continues stimulating postsynaptic 5-HT receptors. Acutely, this raises synaptic serotonin within hours. The therapeutic antidepressant effect, however, typically takes two to four weeks (sometimes up to six to eight) because it depends on downstream adaptations: desensitization of presynaptic autoreceptors, changes in receptor density, and gene-expression-driven neuroplasticity. This gap between pharmacologic action and clinical benefit is the single most important teaching point for adherence — patients who expect immediate relief may stop the drug before it has had a chance to work, and early treatment may transiently worsen anxiety or agitation before benefit emerges.
The agents and how they differ
All six SSRIs share the core mechanism but are not interchangeable in practice.
- Fluoxetine has the longest half-life of the class, with an active metabolite extending effective duration further; this makes withdrawal symptoms less likely if a dose is missed but also means the drug lingers in the body long after stopping, which matters for drug-interaction timing.
- Paroxetine has one of the shortest half-lives and the strongest anticholinergic activity in the class, giving it the most pronounced discontinuation syndrome and the most sedation/weight gain potential.
- Sertraline sits in the middle for half-life and is often favored for its relatively cleaner interaction profile and broad indication approval.
- Citalopram and its S-enantiomer escitalopram are structurally similar; citalopram carries a dose-dependent QT-interval prolongation warning, making it less ideal in patients with cardiac conduction concerns or other QT-prolonging drugs.
- Fluvoxamine is used heavily for obsessive-compulsive disorder and is notable for potent inhibition of CYP1A2 and CYP2C19.
CYP450 involvement matters clinically because several SSRIs (paroxetine and fluvoxamine strongly, fluoxetine moderately) inhibit hepatic enzymes such as CYP2D6, CYP3A4, CYP1A2, and CYP2C19. This can raise blood levels of co-administered drugs metabolized by those pathways (certain beta-blockers, antiarrhythmics, other psychotropics), so a new SSRI prescription should always prompt a medication-interaction review. Sertraline, citalopram, and escitalopram are generally considered to have gentler CYP interaction profiles, though not interaction-free.
Why SSRIs are first-line
Before SSRIs, tricyclic antidepressants and MAO inhibitors were standard, but both carry serious overdose risk: tricyclics cause cardiotoxicity and seizures in overdose, and MAO inhibitors risk hypertensive crisis with dietary tyramine or interacting drugs. SSRIs, by contrast, have a wide therapeutic index and rarely cause fatal overdose when taken alone, which is a major reason they became first-line across depression and anxiety-spectrum disorders despite not being more effective drug-for-drug than older classes.
Indications beyond depression
SSRIs are approved or commonly used for generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder (often at higher relative intensity of treatment than for depression), post-traumatic stress disorder, bulimia nervosa (fluoxetine specifically), and premenstrual dysphoric disorder. This broad utility reflects serotonin's role in mood, fear circuitry, and impulse regulation.
Adverse effects
Common early effects include nausea, GI upset, headache, and either insomnia or somnolence depending on the agent and the individual. Sexual dysfunction (decreased libido, delayed orgasm) is common, dose-related, and a leading cause of discontinuation, so patients should be told to report it rather than silently stop the drug. Weight change can occur in either direction with long-term use. A clinically important but underrecognized risk is hyponatremia from SIADH (syndrome of inappropriate antidiuretic hormone secretion), which disproportionately affects older adults and can present as confusion, lethargy, or falls — sodium levels warrant monitoring in at-risk patients starting therapy. Citalopram's dose-dependent QT prolongation requires caution with other QT-prolonging drugs or preexisting arrhythmia. Because serotonin affects platelet aggregation, SSRIs modestly increase bleeding risk, which becomes clinically significant when combined with NSAIDs, aspirin, or anticoagulants.
Serotonin syndrome
This is a potentially life-threatening state of excess serotonergic activity, presenting with a triad of mental status changes (agitation, confusion), autonomic instability (hyperthermia, tachycardia, diaphoresis, diarrhea), and neuromuscular abnormalities (tremor, hyperreflexia, clonus, myoclonus). It arises when SSRIs are combined with other serotonergic agents — MAO inhibitors (an absolute contraindication requiring a washout period), other antidepressants, triptans, tramadol, linezolid, and certain illicit drugs. Management is supportive: stopping the offending agents, cooling, and benzodiazepines for agitation in more severe cases.
Discontinuation syndrome and tapering
Abruptly stopping an SSRI, especially a short-half-life agent like paroxetine, can produce dizziness, "brain zaps," irritability, flu-like symptoms, and sensory disturbances. This is not withdrawal in the addictive sense but a physiologic adaptation reaction. SSRIs should be tapered gradually rather than stopped abruptly, and patients should be taught never to discontinue on their own without guidance.
Boxed warning and pregnancy
All antidepressants, including SSRIs, carry a boxed warning about increased risk of suicidal thinking and behavior in children, adolescents, and young adults (up to about age 24), particularly in the first weeks of treatment or after dose changes. This mandates close monitoring for mood worsening, agitation, or emerging suicidal ideation, especially early in treatment. In pregnancy, the decision to use an SSRI weighs the risks of untreated maternal depression against potential fetal and neonatal effects; this is an individualized risk-benefit discussion with the prescriber rather than a blanket recommendation either way.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Imagine your brain has tiny mail carriers delivering a "feel-good" message called serotonin. After delivering the message, the carrier usually gets picked back up right away by a little vacuum so it can be reused. SSRIs jam that vacuum a little, so the feel-good message stays out longer and keeps knocking on doors. But your brain needs time to notice this and rearrange its furniture to respond better — that's why it can take several weeks before someone actually feels better, even though the medicine starts working on day one.
These medicines are picked first by doctors because, compared to older mood medicines, they're much safer if someone accidentally takes too much. But they still need care: taking them with certain other medicines can cause way too much serotonin at once, which makes the body overheat and shake — like flooding a room with too much water. And stopping suddenly can give someone dizzy, zappy, flu-like feelings, so you taper off slowly, like turning down a dimmer switch instead of flipping it off.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
An older adult starts an SSRI and over the next two weeks becomes confused and lethargic. What electrolyte disturbance should the nurse suspect, and why are older adults at particular risk?
Show answer
Hyponatremia from SIADH
The nurse should suspect SIADH-related hyponatremia, since SSRIs can cause the body to retain too much water relative to sodium, and older adults are more vulnerable due to age-related changes in fluid and sodium regulation plus polypharmacy. Confusion and lethargy are classic hyponatremia symptoms that warrant checking sodium levels.
A patient taking an SSRI for six weeks tells you they still don't feel any better and want to stop taking it immediately. What two things should you address in your patient teaching?
Show answer
Explain the delayed onset of action and discourage abrupt discontinuation
The nurse should explain that SSRIs often take several weeks to produce full benefit, so six weeks may still be within the expected window, and should discourage stopping abruptly since that can trigger discontinuation symptoms — instead the patient should discuss any change with the prescriber and taper if a change is warranted.
Quick check
3 questions here. Answers stay hidden until you check.
Which SSRI is most associated with dose-dependent QT-interval prolongation?
Choose an answer, then check it.
Why are SSRIs generally preferred over tricyclic antidepressants and MAO inhibitors as first-line therapy?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.